Peptide Antibiotics Market Size To Reach $6.64 Billion By 2030

January 2025 | Report Format: Electronic (PDF)

Peptide Antibiotics Market Growth & Trends

The global peptide antibiotics market size is estimated to reach USD 6.64 billion by 2030, expanding at a CAGR of 5.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is expected to witness growth opportunities owing to factors such as the increasing research and development activities in field of peptide antibiotics coupled with high number of drug approvals. Moreover, surge in cases of antimicrobial resistance cases and possibility of side effects from the conventional antibiotics are also expected to drive the market during the forecast period.

Increasing prevalence of cancer and other infectious diseases are expected to propel the growth over the forecast period. For instance, according to the CDC, United States reported 1,752,735 new cancer cases along with 599,589 deaths in 2019. For every 100,000 people, 439 new cases were found and 146 people died due to cancer. Further, according to Globocan 2020, U.K. had 457,960 new cases with 179,648 deaths in 2020. The most common types of malignancies were breast, prostate cancer and Non-Hodgkin’s lymphoma.

There are some of the peptide antibiotics which are used to treat cancers such as, NHL, Hodgkin’s lymphoma, and certain types of skin malignancies. According to Globocan 2020, there were 5,44,352 Non-Hodgkin lymphoma cases and 83,087 Hodgkin’s lymphoma cases. The efficiency of various existing products is expected to result into higher revenues owing to doctor recommendations . For instance, BLEOMYCIN for injection USP is the mixture of cytotoxic glycopeptide antibiotics that is isolated from Streptomyces verticillus and is used for the treatment of testicular carcinoma, squamous cell carcinoma, and various types of lymphomas.

Moreover, ongoing product approvals and strategic initiatives undertaken by market players such as partnerships, collaborations, product launches, and expansions are expected to fuel market growth during forecast period. For instance, in July 2021, AbbVie Inc announced that the U.S. FDA approved DALVANCE for the treatment of acute bacterial skin and skin structure infections in pediatric patients from birth. Moreover, in July 2020, Sandoz International GmbH announced introduction of Daptomycin injection 500 mg, a generic version of Cubicin, in the U.S. market for the treatment of adult patients with complicated skin and skin structure infections and several type of bloodstream infections.

key Request a free sample copy or view report summary: Peptide Antibiotics Market Report

Peptide Antibiotics Market Report Highlights

The non-ribosomal synthesized peptide antibiotics segment dominated the market and accounted for 72.79% of the global revenue in 2024.
The hospital pharmacies segment dominated the market with a market share of 43.96% in 2024.
Asia Pacific region is expected to witness the highest CAGR over the forecast period owing to factors such as, rising prevalence of infectious diseases, and availability of large patient pool
The North America peptide antibiotics market is growing steadily, driven by increasing demand for effective solutions to combat complex infections such as hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).

Peptide Antibiotics Market Segmentation

Grand View Research has segmented the global peptide antibiotics market based on product, disease, route of administration, distribution channels, and region:

Peptide Antibiotics Product Outlook (Revenue, USD Million, 2018 - 2030)